Proteolytic activation of heparin-binding EGF-like growth factor by membrane-type matrix metalloproteinase-1 in ovarian carcinoma cells
β Scribed by Naohiko Koshikawa; Hiroto Mizushima; Tomoko Minegishi; Fuyuki Eguchi; Fusanori Yotsumoto; Kazuki Nabeshima; Shingo Miyamoto; Eisuke Mekada; Motoharu Seiki
- Book ID
- 108586900
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 611 KB
- Volume
- 102
- Category
- Article
- ISSN
- 1347-9032
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Imatinib mesylate is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit kinases. Inhibition of BCR-ABL and c-kit accounts for its clinical activity in leukemia and sarcoma, respectively. In this report, we describe other cellular targets for imatinib.
Hepatocyte growth factor/scatter factor (HGF/SF) contributes to the malignant progression of human gliomas. We investigated the effect of HGF/SF on matrix metalloproteinase-2 (MMP-2), membrane type 1 matrix metalloproteinase (MT1-MMP) and tissue inhibitors of metalloproteinases (TIMPs), expressions